Q2-26 saw 12% revenue growth, with Proteins and Analytics segments leading gains and adjusted EPS up 46% year-over-year. FY26 guidance was raised for both organic revenue and EPS, and a definitive agreement to acquire BioLife Solutions was announced.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.